Tokyo, Oct. 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059351) titled 'Effect of Imidazole Dipeptide Supplementation on Lipid Metabolism During Aerobic Exercise' on Oct. 9.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Randomized
Blinding - Double blind -all involved are blinded
Control - Placebo
Primary Sponsor:
Institute - Daito Bunka University
Condition:
Condition - healthy individuals
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The study examines the effects of four-week continuous imidazole dipeptide intake on lipid metabolism during aerobic exercise and on changes in oxidative stress markers before and after exercise in male university students who belong to the university rugby club.
Basic objectives2 - Others
Intervention:
Interventions/Control_1 - Participants will consume 2.0 g of imidazole dipeptides or placebo daily for four weeks.
Interventions/Control_2 - Participants will consume 2.0 g of imidazole dipeptides or placebo daily for four weeks.
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male
Key inclusion criteria - 1. Male university students aged 18 to 25.
2. No history of major injury or surgery within the past six months.
3. Deemed safe to participate by the physician based on self-reported medical history and medication use.
Key exclusion criteria - 1. History of cardiovascular, respiratory, or metabolic diseases
2. Allergies to supplement ingredients (e.g., chicken-derived protein, beta-alanine)
3. Current use of substances listed on the 2025 WADA Prohibited List
Target Size - 30
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 06 Month 23 Day
Date of IRB - 2025 Year 07 Month 25 Day
Anticipated trial start date - 2025 Year 09 Month 22 Day
Last follow-up date - 2025 Year 12 Month 10 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067880
Disclaimer: Curated by HT Syndication.
